Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.67 |
| ▸ | GRM5 | P41594 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577310 | 0.93 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL6708175 | 0.93 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL5795083 | 0.93 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL6110694 | 0.92 | CYP1A2 (0.75) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| Hydrochloric Acid SCHEMBL27538332 | 0.92 | CYP1A2 (0.97) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL14334739 | 0.91 | MAPT (0.78) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL14334891 | 0.89 | MAPT (0.76) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL135679 | 0.89 | LMNA (1.00) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL2898307 | 0.89 | CYP1A2 (0.75) | CYP1A2CYP2C9CYP2C19LMNAMAPT | |
| SCHEMBL9639441 | 0.89 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366691-B1 | THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO LTD (CN) | 2015-04-15 | — | — | EP | claimed |
| US-8609851-B2 | Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof | BEIJING YILING BIOENGINEERING CO., LTD. (CN) | 2013-12-17 | — | — | US | claimed |
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2012-03-22 | — | — | US | claimed |
| EP-2366691-A1 | THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | Beijing Yiling Bioengineering Co., Ltd. (CN) | 2011-09-21 | — | — | EP | claimed |
| EP-2366691-B1 | THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO LTD (CN) | 2015-04-15 | — | — | EP | disclosed |
| US-8940770-B2 | Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof | BEIJING YILING BIOENGINEERING CO., LTD. (CN) | 2015-01-27 | — | — | US | disclosed |
| US-8940770-B2 | Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof | BEIJING YILING BIOENGINEERING CO., LTD. (CN) | 2015-01-27 | — | — | US | disclosed |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2014-03-13 | — | — | US | disclosed |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2014-03-13 | — | — | US | disclosed |
| US-8609851-B2 | Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof | BEIJING YILING BIOENGINEERING CO., LTD. (CN) | 2013-12-17 | — | — | US | disclosed |
| US-8609851-B2 | Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof | BEIJING YILING BIOENGINEERING CO., LTD. (CN) | 2013-12-17 | — | — | US | disclosed |
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2012-03-22 | — | — | US | disclosed |
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2012-03-22 | — | — | US | disclosed |
| EP-2366691-A1 | THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | Beijing Yiling Bioengineering Co., Ltd. (CN) | 2011-09-21 | — | — | EP | disclosed |
| EP-2366691-A1 | THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | Beijing Yiling Bioengineering Co., Ltd. (CN) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010048880-A1 | THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | 北京以岭生物工程有限公司 (CN) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | ENPP1, DPYD, NME2 | CYP1A2 110/4885CYP2C9 50/4885CYP2C19 8/4885 |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | ENPP1, DPYD, NME2 | CYP1A2 110/4885CYP2C9 50/4885CYP2C19 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.